U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process (Drugs)
  4. Drug Development Tool Qualification Programs
  5. CDER Biomarker Qualification Program
  6. Context of Use
  1. Drug Development Tool Qualification Programs

Context of Use

Context of Use

What is a context of use (COU) for a biomarker?

The COU is a concise description of the biomarker’s specified use in in drug development. The COU includes two components: (1) the BEST biomarker category and (2) the biomarker’s intended use in drug development. Each biomarker qualification effort should identify a single COU. 

A COU is generally written to be consistent with the following structure:

[BEST biomarker category] to [drug development use].

Examples of Biomarker Intended Use in Drug Development

  • Defining inclusion/exclusion criteria
  • Defining treatment allocation arms
  • Cessation of a patient’s participation in a clinical trial
  • Establishing a drug’s proof of concept in a patient population
  • Supporting clinical dose selection
  • Serving to enrich clinical trial for an event or population of interest
  • Evaluating treatment response

Note that a drug development use may also include descriptive information such as the patient population, disease or disease stage or model system; stage of drug development; and/or mechanism of action of the therapeutic intervention.

See the graphic below for examples of how a biomarker category and drug development use are related.

BEST Biomarker Category and Examples of Corresponding Drug Development Uses

Examples of Contexts of Use With Respect to Biomarker Category

 

Examples of COUs

  • Predictive biomarker to enrich for enrollment of a sub group of asthma patients who are more likely to respond to a novel therapeutic in Phase 2/3 clinical trials.
  • Prognostic biomarker to enrich the likelihood of hospitalizations during the timeframe of a clinical trial in phase 3 asthma clinical trials. 
  • Safety biomarker for the detection of acute drug-induced renal tubule alterations in male rats

Important Information for Requestors

 Contact us at: CDER-BiomarkerQualificationProgram@fda.hhs.gov